The development of imatinib and other tyrosine kinase inhibitors (TKIs) targeting the ABL1 tyrosine kinase allowed a dramatic change in CML prognosis, with long-term control of the disease in most individuals [2]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.